Navigation Links
HRID Announces Growth and Expansion
Date:3/1/2012

ancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.

CONTACT:

Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... the Piper Jaffray 26 th Annual Healthcare Conference in ... the Piper Jaffray conference is scheduled for 8:00 am EST (5:00 ... webcast, and the webcast can be accessed via the Investor Relations ... of the webcast will be archived for 30 days on the ...
(Date:11/21/2014)... THE WOODLANDS, Texas , Nov. 21, 2014 /PRNewswire/ ... announced the pricing of its previously announced underwritten public ... pursuant to an effective shelf registration statement. The offering ... a public offering price of $1.005 per share.  Lexicon ... purchase up to 7,462,687 additional shares of common stock.  ...
(Date:11/18/2014)... Nov. 18, 2014  Sanguine Biosciences – a ... and study recruitment – will use its proprietary ... help Pfizer Inc. find and recruit people diagnosed ... family members to participate in voluntary research, which ... mutations and hopefully aid in informing the development ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
(Date:11/21/2014)... News) -- While levels of testosterone and other reproductive ... their emotional health and quality of their relationships have ... Testosterone is the main sex hormone in men. But, ... hormone, the researchers noted. The researchers analyzed data ... a long-term study of women,s health. They found that ...
(Date:11/21/2014)... /> THURSDAY, Nov. 20, 2014 (HealthDay News) -- Kidney ... can do for another. And now a new study finds ... in life are benefiting from policies that give them priority ... for almost 6,300 of the 16,900 kidney transplants that took ... information supplied by the study researchers. At the ...
(Date:11/18/2014)... 18, 2014 Cristcot Inc., a ... and commercialization of specialized drug delivery systems, today ... Cristcot a patent for the technology, which encompasses ... , The patent was awarded to the ... have been assigned to Cristcot Inc. The patented ...
(Date:11/18/2014)... Medicationdiscountcard.com's blog offers health ... company's reputation for helping consumers save money at ... offer at http://blog.medicationdiscountcard.com/ . , Consumers need ... Affordable Care Act and the state health benefit ... about a variety of prescription drug and health ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... experimental antibody drug could prove effective at lowering LDL ... with cholesterol-lowering statin medications. That,s the conclusion of ... Association annual meeting in Chicago. The drug, alirocumab, ... widely used alternative to statins, Zetia, said lead researcher ...
Breaking Medicine News(10 mins):Health News:Testosterone Plays Minor Role in Older Women's Sex Lives, Study Finds 2Health News:Study Supports Giving Kidney Donors Priority When They Need a Kidney 2Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3
... in training have a 17 percent less chance of ... surgery at non-teaching hospitals, according to results of a ... the Annals of Thoracic Surgery. , Theres a ... because of training issues, and concerns are frequently voiced ...
... Senate Letter asks Lawmakers to Reject Funding Reductions ... Reform Much More,Difficult to Achieve, Letter Draws ... March 4 The Council for Quality,Respiratory Care ... home oxygen,therapy providers and manufacturers who provide care ...
... and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals,today ... healthy subjects in,a Phase I study of AFN-1252, ... class of fatty acid biosyntheis inhibitors. The study ... of a single,escalating oral dose. Affinium believes that ...
... Data from one of the first genome-wide association studies ... in part by The Michael J. Fox Foundation for ... researchers through the National Human Genome Research Institute (NHGRI) ... of the National Institutes of Health (NIH). NHGRI hopes ...
... experience a significant improvement in their quality of ... new research published in the March 2008 issue ... The German study evaluated the quality of life ... Cochlear Implant Questionnaire (NCIQ), a self-administered assessment that ...
... the users risk of head and neck cancer, according to ... Otolaryngology Head and Neck Surgery. , The small sample ... found that among 75 cases of head and neck cancer, ... neck cancer in marijuana users was the same (1.0) as ...
Cached Medicine News:Health News:Risk of surgery for lung cancer lower at teaching hospitals 2Health News:Bi-Partisan Members of United States Senate Formally Raise Concerns About Proposed Cuts to Medicare's Home Oxygen Benefit 2Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2Health News:Genome-wide association study on Parkinson's disease finds public home at NIH 2Health News:Genome-wide association study on Parkinson's disease finds public home at NIH 3Health News:Genome-wide association study on Parkinson's disease finds public home at NIH 4Health News:Genome-wide association study on Parkinson's disease finds public home at NIH 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: